“Dual‐Hit” Photothermal and Immunogenicity Activation by Structurally Simple Carbon Dots‐Doped Hydrogel
Source abstract
Abstract
ABSTRACT Effective tumor treatment can only be achieved by combining short‐acting, localized therapy with long‐acting, systemic anti‐tumor immunogenicity. Herein, we report a “dual‐hit” synergistic photothermal‐immunotherapy based on a multifunctional carbon dot‐doped polymeric hydrogel with loaded oxaliplatin. Under laser irradiation, the hydrogel generates an initial photothermal ablation (“first‐hit”) while triggering OXA release. The released OXA induces potent immunogenic cell death and thereby activates long‐standing antitumor immune response (“second‐ICD, Therapy, carbon dots, hydrogel, photothermalhit”). This “dual‐hit” therapeutic strategy is successfully performed in tumor‐bearing mice.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Carbon and Quantum Dots Applications · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Breast Surgery First Hospital of Quanzhou Affiliated to Fujian Medical University Quanzhou China
School of Chemistry and Biological Engineering Beijing Key Laboratory for Bioengineering and Sensing Technology University of Science and Technology Beijing Beijing China
Department of Radiation Oncology First Hospital of Quanzhou Affiliated to Fujian Medical University Quanzhou China
Department of Chemistry University of Chicago Chicago Illinois USA
Funding
Natural Science Foundation of Fujian Province
References (38)
Show source-provided references
1. 10.1038/s41586‐019‐1730‐110.1038/s41586‐019‐1730‐1 ↗
2. 10.1016/j.pmatsci.2024.10137510.1016/j.pmatsci.2024.101375 ↗
3. 10.1002/adtp.20240034710.1002/adtp.202400347 ↗
4. 10.1002/adma.20200861510.1002/adma.202008615 ↗
5. 10.1002/adma.20240298110.1002/adma.202402981 ↗
6. 10.1002/adfm.20251008910.1002/adfm.202510089 ↗
7. 10.1002/anie.20230357010.1002/anie.202303570 ↗
8. 10.1016/j.ijpharm.2019.05.05610.1016/j.ijpharm.2019.05.056 ↗
9. 10.1038/s41467‐022‐30306‐710.1038/s41467‐022‐30306‐7 ↗
10. 10.1038/s41467‐020‐14963‐010.1038/s41467‐020‐14963‐0 ↗
11. 10.1016/j.ccr.2024.21581710.1016/j.ccr.2024.215817 ↗
12. 10.1080/17435889.2025.248934210.1080/17435889.2025.2489342 ↗
13. 10.1002/adfm.20160147810.1002/adfm.201601478 ↗
14. 10.1038/s41467‐024‐53646‐y10.1038/s41467‐024‐53646‐y ↗
15. 10.1002/ijc.3549610.1002/ijc.35496 ↗
16. 10.1038/s41423‐024‐01245‐810.1038/s41423‐024‐01245‐8 ↗
17. 10.1002/adfm.20230701310.1002/adfm.202307013 ↗
18. 10.1002/jbt.7032710.1002/jbt.70327 ↗
19. 10.1039/D5CC03574K10.1039/D5CC03574K ↗
20. 10.1111/imr.1327110.1111/imr.13271 ↗
21. 10.1111/imr.1330110.1111/imr.13301 ↗
22. 10.1002/tcr.20240010010.1002/tcr.202400100 ↗
23. 10.1016/j.jconrel.2022.03.05910.1016/j.jconrel.2022.03.059 ↗
24. 10.1016/j.jconrel.2024.11.00510.1016/j.jconrel.2024.11.005 ↗
25. 10.1016/j.nano.2020.10226510.1016/j.nano.2020.102265 ↗
26. 10.1016/j.cej.2025.16130710.1016/j.cej.2025.161307 ↗
27. 10.1016/j.colsurfb.2025.11500110.1016/j.colsurfb.2025.115001 ↗
28. 10.1039/D5MH00676G10.1039/D5MH00676G ↗
29. 10.1039/D3QI02602G10.1039/D3QI02602G ↗
30. 10.1016/j.actbio.2023.02.01210.1016/j.actbio.2023.02.012 ↗
31. 10.1002/chem.20230294810.1002/chem.202302948 ↗
32. 10.1016/j.biomaterials.2019.11939510.1016/j.biomaterials.2019.119395 ↗
33. 10.1016/j.immuni.2024.10.01210.1016/j.immuni.2024.10.012 ↗
34. 10.1002/adfm.20242556510.1002/adfm.202425565 ↗
35. 10.1038/s41568‐024‐00787‐310.1038/s41568‐024‐00787‐3 ↗
36. 10.1038/s41467‐024‐50769‐010.1038/s41467‐024‐50769‐0 ↗
37. 10.1016/j.jconrel.2019.01.02710.1016/j.jconrel.2019.01.027 ↗
38. 10.1002/adfm.20230724110.1002/adfm.202307241 ↗